🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

Recruitingn/aAges any - anyAllChristoph Königs
NCT05802836 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Severe congenital hemophilia A (CHA) * Treatment with emicizumab irrespective of any other treatment * Informed consent Exclusion Criteria: * No therapy with emicizumab * Immunosuppressive therapy * HIV-infection with CD4 (cluster of differentiation 4) cells \<200/µl
💊

What it tests

  • no interventions
📍

Where

1 site
University Hospital Frankfurt, Goethe University
Frankfurt am Main, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy